Less Ads, More Data, More Tools Register for FREE

Pin to quick picksThruvision Grp Regulatory News (THRU)

Share Price Information for Thruvision Grp (THRU)

Share Price is delayed by 15 minutes
Get Live Data
0.70    0.00 (0.00%)
Bid:
0.65
Ask:
0.75
Spread: 0.10 (15.385%)
Market Cap: £3.13m
THRU Live PriceLast checked at - London Stock Exchange

Intraday Thruvision Grp Share Chart

Material Contract Award and Trading Update

2 Jul 2025 07:00

RNS Number : 3083P
Thruvision Group PLC
02 July 2025
 

 

2 July 2025

Thruvision Group plc

 

Material contract award and trading update

 

The Board of Thruvision Group plc (AIM: THRU) (the "Company", "Thruvision" or, together with its subsidiary undertakings, the "Group"), the leading international provider of walk-through security technology, announces a material contract award and provides an update on current trading and the Group's cash position.

Contract win

The Group is pleased to announce that it has secured a material contract for 20 systems, valued in excess of £1 million, from a new government customer in Asia (the "Contract"). The Contract was secured through close collaboration with the Group's regional partner and builds on the recent successful deployment of multiple WalkTHRU screening lanes at a major cultural event in Asia. The order is for Thruvision's highest specification systems and is scheduled to be delivered during the next few weeks. It underscores growing demand for the Group's advanced security solutions in high-profile government applications. This contract resulted from one of the "Material Opportunities" referred to in previous announcements.

Current Trading

Order intake for the first quarter of FY26 ended 30 June 2025, including the Contract detailed above, was £2.3 million, an increase of 145% on the same period in the prior year. This strong performance is in line with the Board's expectations for the quarter. The Group's sales pipeline has a number of Material Opportunities in Asia and other regions which the Board is confident will convert to revenue during both the current and next financial year. The Group's US business has also traded well, with a number of repeat unit purchases from existing Retail Distribution customers. In addition, the Group was awarded its first contract to provide a unit to a UK prison, following on from the ongoing success in a European prison service.

Cash Position

On 23 June 2025, the Board announced that, at that time, its reasonable expectation was that the Group's cash resources would last until the end of September 2025.

Given the recent encouraging trading performance and the continued strength of the sales pipeline, including both smaller and more material opportunities, the Board now considers that the Group's cash resources will be sufficient to last until the end of the calendar year, although this is dependent on future trading performance and conversion of the sales pipeline in line with the Board's reasonable expectations.

For further information, please contact:

Thruvision Group plc

Tom Black, Executive Chairman +44 (0)1235 425400

Victoria Balchin, Chief Executive Officer

Investec Investment Banking (NOMAD & Broker)

Patrick Robb / James Rudd / Sebastian Lawrence +44 (0)20 7597 5970

 

About Thruvision (www.thruvision.com)

 

Thruvision is the leading developer, manufacturer and supplier of advanced AI-based walk- through security technology internationally. Its technology is deployed in more than 30 countries around the world by government and commercial organisations in a wide range of security situations, where large numbers of people need to be screened quickly, safely and efficiently. Thruvision's patented technology is uniquely capable of detecting concealed objects in real time using advanced AI-based detection algorithms. The Group's offices are near Oxford and Washington DC.

 

Important information

 

This announcement may include statements that are, or may be deemed to be, 'forward-looking statements' (including words such as 'believe', 'expect', 'estimate', 'intend', 'anticipate' and words of similar meaning). By their nature, forward-looking statements involve risk and uncertainty since they relate to future events and circumstances, and actual results may, and often do, differ materially from any forward-looking statements. Any forward-looking statements in this announcement reflect management's view with respect to future events as at the date of this announcement. Save as required by applicable law, the Company undertakes no obligation to publicly revise any forward-looking statements in this announcement, whether following any change in its expectations or to reflect events or circumstances after the date of this announcement.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
TSTPKDBDCBKDCOK
Date   Source Headline
19th Jun 20267:00 amRNS-RRetail Distribution orders received Sensormatic
14th May 20267:00 amRNS-RNew Strategic Partnerships
7th May 202611:45 amRNSBlocklisting cancellation and interim review
7th May 202611:45 amRNSBlocklisting cancellation and interim review
8th Apr 20267:00 amRNSFY26 Trading Update
13th Mar 20267:00 amRNSUS Aviation Contract Award
13th Mar 20267:00 amRNSUS Aviation Contract Award
19th Feb 20267:00 amRNSHolding(s) in Company
19th Feb 20267:00 amRNSContract awards into UK custodial facilities
12th Feb 20267:00 amRNS-RFirst UK “Screening as a Service” Sales
22nd Jan 20267:00 amRNS-RUK Retail Distribution Contract Award
20th Jan 20267:00 amRNSSouth-East Asian Mass Transit Contract Award
12th Jan 20267:00 amRNSHolding(s) in Company
5th Jan 202611:27 amRNSAward of Share Options
19th Dec 20251:07 pmRNS-RUS Retail Distribution Contract Award
19th Dec 20251:07 pmRNS-RUS Retail Distribution Contract Award
16th Dec 20257:00 amRNSHolding(s) in Company
11th Dec 20257:00 amRNSHolding(s) in Company
8th Dec 20257:00 amRNS-RImminent contract award
4th Dec 20257:00 amRNSHolding(s) in Company
28th Nov 20253:45 pmRNSHolding(s) in Company
26th Nov 20257:00 amRNSHolding(s) in Company
25th Nov 20257:00 amRNSInterim Results and Trading Update
6th Nov 20254:30 pmRNSBlock listing Interim Review
6th Nov 20254:30 pmRNSBlock listing Interim Review
23rd Oct 202510:53 amRNSResult of AGM
23rd Oct 20257:00 amRNSAGM Statement and Trading Update
6th Oct 20251:49 pmRNS-RNPSA Testing Update
30th Sep 202512:33 pmRNSHolding(s) in Company
29th Sep 202512:04 pmRNSHolding(s) in Company
29th Sep 202511:26 amRNSDirector/PDMR Shareholding
25th Sep 20257:00 amRNSNotice of AGM
19th Sep 20257:00 amRNSFinal Results
15th Sep 202512:40 pmRNSHolding(s) in Company
9th Sep 20257:00 amRNS-RAdditions to Value-Added Reseller Network
1st Aug 20259:46 amRNSHolding(s) in Company
1st Aug 20257:00 amRNSHolding(s) in Company
31st Jul 20255:00 pmRNSTotal Voting Rights
31st Jul 20252:37 pmRNSHolding(s) in Company
31st Jul 20252:01 pmRNSHolding(s) in Company
31st Jul 202510:32 amRNSHolding(s) in Company
31st Jul 20257:00 amRNSHolding(s) in Company
29th Jul 20251:54 pmRNSHolding(s) in Company
28th Jul 202510:50 amRNSResult of GM and completion of Capital Raising
28th Jul 20257:00 amRNSChange of Adviser
8th Jul 20257:00 amRNSResult of Retail Offer & Notice of General Meeting
4th Jul 20257:05 amRNSWRAP Retail Offer
4th Jul 20257:00 amRNSResult of Review & Proposed Capital Raise
2nd Jul 20257:00 amRNSMaterial Contract Award and Trading Update
23rd Jun 20251:50 pmRNSHolding(s) in Company

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.